Skip to content
Walvax logo — Help everyone live a healthy life!

Walvax

Help everyone live a healthy life!

Founded 2001 China Kunming, China 79 employees Post-IPO Equity Total: $72.80M Biotechnology, Health Care +1

General Information

Company Name Walvax
Founded Year 2001
Location China Kunming, China
Employees 79
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Walvax. To contact Walvax, visit en.walvax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Walvax compare?

A PDF of Walvax and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Walvax soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Walvax

Walvax is a biotechnology company founded in 2001, with a mission to "Help everyone live a healthy life!" Headquartered in Kunming, China, the company went public via IPO in 2010 (300142.SZ). Ever since, the company has been expanding from traditional vaccines to innovative vaccines. With a focus on producing efficacious, quality, innovative, and affordable products, their ultimate goal is to protect people from the world’s deadliest diseases. In August 2014, Walvax received a significant investment of $72.80M in post-IPO equity. This investment is expected to further drive the company's research and development, manufacturing, and distribution activities, positioning it as a leading vaccine producer both domestically and globally. With a strong emphasis on safety and quality, Walvax is dedicated to revolutionizing the vaccine industry.

Business keywords: Biological pharmaceutical company, Vaccines, Blood products, Biomedicine products, Meningococcal polysaccharide vaccine, Haemophilus influenzae type b conjugate vaccine, Infectious diseases, Preventive healthcare, Public health, Research and development, Bio-medicine, Medical innovation, China, Kunming

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $72.80M -
08 Aug 2014

Walvax Alternatives & Competitors

View All Alternatives
Walvax vs
Affinivax Inc.
Affinivax Inc. United States

Affinivax was acquired by GSK in August 2022. Affinivax is a clinical stage biotechnology company de...

Grant
23 employees
Biotechnology, Health Care
Walvax vs

A joint venture between SEEK Group and hVIVO, part of Open Orphan plc, to accelerate the development...

Seed
2 employees
Biotechnology, Health Care
Walvax vs
Baseimmune
Baseimmune United Kingdom

Pioneering the next generation of active immunotherapies for chronic diseases

Series A
29 employees
Biotechnology, Health Care

FAQ About Walvax

Help everyone live a healthy life!
Walvax was founded in 2001.
Walvax is headquartered in Kunming, China.
Walvax operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biological pharmaceutical company, Vaccines, Blood products and Biomedicine products.
Walvax has approximately 79 employees.
Walvax has completed 1 funding round, raising a total of $72.80M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Walvax include Affinivax Inc., IMUTEX Ltd, Baseimmune, Biovaccines Nigeria Limited, 江苏为真生物医药技术股份有限公司. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Walvax and Affinivax Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Walvax, https://bouncewatch.com/company/walvax-biotechnology, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout